Skip to main
ALMS

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Alumis is projected to have a positive outlook based on their promising pipeline, positive phase III data in psoriasis, and an ongoing global clinical trial for TYK2 inhibition in systemic lupus erythematosus. Furthermore, the company's positive data could potentially lead to expansion of their pipeline into other indications beyond psoriasis and SLE, increasing their addressable market and potential for revenue growth. Their current cash position also provides financial stability for operations and future expansions.

Bears say

Alumis is a biopharmaceutical company with a promising pipeline focused on developing TYK2 inhibitors for autoimmune and neurodegenerative diseases. However, the company faces significant competition from other therapies, potential challenges in commercialization, and risks associated with clinical trials and regulatory approval. Additionally, the need for continued funding may result in share dilution for shareholders.

Alumis Inc (ALMS) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 9 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.